HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Making Artificial Intelligence systems robustly perceive humans remains one of the most intricate challenges in computer ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...